FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194598552> ?p ?o ?g. }

• W3194598552 abstract "Background: Anti-inflammatory therapy has been proposed as a promising treatment for coronary heart disease (CHD) that could reduce residual inflammation risk (RIR) and therefore major adverse cardiovascular events. We implemented a systematic review and meta-analysis of randomized controlled trials (RCTs) to assess the clinical benefits of anti-inflammatory agents in patients with CHD based on secondary cardiovascular prevention. Methods: We systemically searched the PubMed, Embase, and Cochrane Library databases for RCTs (published between Jan 1, 1950, and June 1, 2021; no language restrictions) that focused on anti-inflammatory therapy for coronary heart disease. Our primary end points of interest were a composite of all-cause death, recurrent myocardial infarction and stroke. We processed pooled data using a random-effects model. Results: Of 1497 selected studies, 18 studies with 67,449 participants met our inclusion criteria and were included in the present meta-analysis. Comparing anti-inflammatory agents with placebo, there was no significant decrease in risk of primary end points, secondary end points, all-cause mortality, cardiac mortality, recurrent myocardial infarction, stroke or revascularization. Further subgroup analysis indicated that anti-inflammatory agents led to a significant reduction in secondary end points (OR 0.87, CI 0.77–0.99; P = 0.03), recurrent myocardial infarction (OR 0.86, CI 0.78–0.95; P = 0.003) and revascularization (OR 0.81, CI 0.70–0.92; P = 0.001) in patients with stable CHD compared with placebo. Moreover, stable CHD patients had a lower propensity for recurrent myocardial infarction than acute coronary syndrome (ACS) patients when using anti-inflammatory agents ( P = 0.03). The colchicine subgroup analysis showed that colchicine yielded a promising reduction in the primary end points (OR 0.81, CI 0.70–0.95; P = 0.009) compared with placebo. Anti-inflammatory agents were associated with a higher risk of infection (OR 1.13, CI 1.03–1.23; P = 0.007) and negligible effects on cancers (OR 0.98, CI 0.90–1.06; P = 0.61). Conclusion: Anti-inflammatory agents appear to have beneficial effects in reducing the risk of recurrent myocardial infarction in patients with stable CHD, albeit at the cost of increased infection. Notably, colchicine demonstrates a promising cardioprotective effect with a lower incidence of major cardiovascular events and thus is a potential therapeutic strategy for stable CHD patients. Systematic Review Registration: PROSPERO, identifier CRD42021245514." @default.
• W3194598552 created "2021-08-30" @default.
• W3194598552 creator A5002285545 @default.
• W3194598552 creator A5010643810 @default.
• W3194598552 creator A5011102706 @default.
• W3194598552 creator A5026280832 @default.
• W3194598552 creator A5030202096 @default.
• W3194598552 creator A5031106663 @default.
• W3194598552 creator A5031528894 @default.
• W3194598552 creator A5034132613 @default.
• W3194598552 creator A5035330165 @default.
• W3194598552 creator A5051236027 @default.
• W3194598552 creator A5075012194 @default.
• W3194598552 creator A5075415907 @default.
• W3194598552 creator A5084136821 @default.
• W3194598552 date "2021-08-25" @default.
• W3194598552 modified "2023-09-27" @default.
• W3194598552 title "Anti-inflammatory Therapies for Coronary Heart Disease: A Systematic Review and Meta-Analysis" @default.
• W3194598552 cites W1042476336 @default.
• W3194598552 cites W1512569924 @default.
• W3194598552 cites W1572528121 @default.
• W3194598552 cites W1705607911 @default.
• W3194598552 cites W1978608317 @default.
• W3194598552 cites W1991883893 @default.
• W3194598552 cites W2005501262 @default.
• W3194598552 cites W2036632357 @default.
• W3194598552 cites W2087957038 @default.
• W3194598552 cites W2093076255 @default.
• W3194598552 cites W2095709591 @default.
• W3194598552 cites W2113187337 @default.
• W3194598552 cites W2113978145 @default.
• W3194598552 cites W2122865912 @default.
• W3194598552 cites W2124964328 @default.
• W3194598552 cites W2146461935 @default.
• W3194598552 cites W2165241435 @default.
• W3194598552 cites W2213668027 @default.
• W3194598552 cites W2337488815 @default.
• W3194598552 cites W2747496024 @default.
• W3194598552 cites W2748400555 @default.
• W3194598552 cites W2754330582 @default.
• W3194598552 cites W2803671762 @default.
• W3194598552 cites W2860095218 @default.
• W3194598552 cites W2871181805 @default.
• W3194598552 cites W2899885364 @default.
• W3194598552 cites W2914237180 @default.
• W3194598552 cites W2986700515 @default.
• W3194598552 cites W3009251297 @default.
• W3194598552 cites W3009526634 @default.
• W3194598552 cites W3012527193 @default.
• W3194598552 cites W3016436366 @default.
• W3194598552 cites W3072462011 @default.
• W3194598552 cites W3081761942 @default.
• W3194598552 cites W3082109297 @default.
• W3194598552 cites W3092669347 @default.
• W3194598552 cites W3120984681 @default.
• W3194598552 cites W3127172188 @default.
• W3194598552 cites W3180226881 @default.
• W3194598552 cites W4248707146 @default.
• W3194598552 doi "https://doi.org/10.3389/fcvm.2021.726341" @default.
• W3194598552 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8424052" @default.
• W3194598552 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34513960" @default.
• W3194598552 hasPublicationYear "2021" @default.
• W3194598552 type Work @default.
• W3194598552 sameAs 3194598552 @default.
• W3194598552 citedByCount "6" @default.
• W3194598552 countsByYear W31945985522021 @default.
• W3194598552 countsByYear W31945985522022 @default.
• W3194598552 countsByYear W31945985522023 @default.
• W3194598552 crossrefType "journal-article" @default.
• W3194598552 hasAuthorship W3194598552A5002285545 @default.
• W3194598552 hasAuthorship W3194598552A5010643810 @default.
• W3194598552 hasAuthorship W3194598552A5011102706 @default.
• W3194598552 hasAuthorship W3194598552A5026280832 @default.
• W3194598552 hasAuthorship W3194598552A5030202096 @default.
• W3194598552 hasAuthorship W3194598552A5031106663 @default.
• W3194598552 hasAuthorship W3194598552A5031528894 @default.
• W3194598552 hasAuthorship W3194598552A5034132613 @default.
• W3194598552 hasAuthorship W3194598552A5035330165 @default.
• W3194598552 hasAuthorship W3194598552A5051236027 @default.
• W3194598552 hasAuthorship W3194598552A5075012194 @default.
• W3194598552 hasAuthorship W3194598552A5075415907 @default.
• W3194598552 hasAuthorship W3194598552A5084136821 @default.
• W3194598552 hasBestOaLocation W31945985521 @default.
• W3194598552 hasConcept C126322002 @default.
• W3194598552 hasConcept C127413603 @default.
• W3194598552 hasConcept C142724271 @default.
• W3194598552 hasConcept C164705383 @default.
• W3194598552 hasConcept C168563851 @default.
• W3194598552 hasConcept C187960798 @default.
• W3194598552 hasConcept C204787440 @default.
• W3194598552 hasConcept C27081682 @default.
• W3194598552 hasConcept C2776478404 @default.
• W3194598552 hasConcept C2777698277 @default.
• W3194598552 hasConcept C2779464278 @default.
• W3194598552 hasConcept C2780645631 @default.
• W3194598552 hasConcept C500558357 @default.
• W3194598552 hasConcept C71924100 @default.
• W3194598552 hasConcept C78519656 @default.
• W3194598552 hasConcept C95190672 @default.
• W3194598552 hasConceptScore W3194598552C126322002 @default.

• next